Currently, no efficient medical or surgical treatment is available for geographic atrophy (GA), also known as the “dry” form of AMD, while anti-vascular endothelial growth factor (VEGF) therapies have been used for treating neovascular AMD, also known as the “wet” form (Campa and Harding, 2011). The gene discussed is VEGFA; the disease is atrophic macular degeneration.